The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

scibase.se

Highlight why customers choose SciBase's products and services with an Analyst Briefing

SC
How SciBase benefits their customers:
Help customers evaluate SciBase products
Why do customers choose SciBase products and services

Work for SciBase?

Compete with SciBase?

Brief our analysts.

Get in front of tech buyers.

100% free.

No pay-to-play nonsense.

Work for SciBase?

Brief our analysts.

Get in front of tech buyers.

100% free.

No pay-to-play nonsense.

You May Also Like

P
PreMD

PreMD Inc. is dedicated to saving and improving people's lives with simple, painless and patient-friendly tests that can detect life-threatening illnesses at a. The company's tests do not require any patient preparation or dietary restrictions and can be performed at the point of care, in a laboratory setting and, in some cases, even at home. The company's cardiovascular risk assessment technology, PREVU* Skin Sterol Test, assesses a patient's risk of heart disease by non-invasively measuring the amount of cholesterol in the skin tissues. PreMD's non- or minimally-invasive tests for early-stage colorectal, lung and breast cancers detect a cancer-associated sugar in a sample of rectal mucus, sputum and breast nipple aspirate fluid, respectively. The company's cancer tests are in development.

Nanomagnetics Instruments Logo
Nanomagnetics Instruments

NanoMagnetics Instruments has been founded in Oxford, UK in 1998. The company's aim was to produce Scanning Hall Probe Microscope (SHPM) for room temperature applications at the beginning. The quantitative and non-invasive magnetic imaging capabilities of hall probe with high resolution are needed for many applications in science and technology. These directed us to embody the company's first product, Room Temperature Scanning Hall Probe Microscope (RT-SHPM) for the market. The another requirement for basic researches in condensed matter physics was for low temperature magnetic imaging applications of hall probes like superconductivity, quantum hall effect, etc.. The company desgined Low Temperature Scanning Hall Probe Microscope (LT-SHPM). The company's design was so flexible and compatible with many cryostats, He3 systems, Dilution Refrigerator systems. This flexilibility enabled us to operate the company's LT-SHPM for milli-Kelvin applications for many hot Low Temperature physics problems. n Recently, Scanning Tunnelling Microscope (STM) and Self-sensing AFM techniques like Quartz Crystal Tuning Fork and Akiyama Sensors options were added both LT and RT SPMs.n In 2002, the company signed a record and produced known Smallest Hall Sensor in the world, 50 nm. It is still unprecedendent spatial resolution limit for the hall sensors with extreme magnetic field resolutions around a couple of mG/u221aHz range at room temperature conditions. The filed resolution is much better for LHe temperatures: 6nT /u221aHz.n However, basic researches and industry still requires higher spatial resolutions. Needs determines the inventions and improvements. At this point, the company have presented the company's new product Low Temperature Magnetic Force Microscope (LT-MFM) for high resolution magnetic imaging, in 2007. The company's MFM depends on fiber interferometer detection technique with alignment free cantilevers. All AFM modes are available for low temperature ranges between 300K and 300mK like, EFM, Scanning Spreading Resistance, etc.n Today, the company are their powerful SPM solution partner in nanoscience and technology with the company's broad product range all around the world. Use this power!

Endologix Logo
Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

W
Wioptix

Wioptix is a company that received a SBIR Phase IB grant for a project entitled: Development of Miniature Endoscopic Imaging Probes for In Vivo Noninvasive Optical Imaging for Early Diagnosis of Lung Cancer. Their Phase I project an Optical coherence tomography (OCT) imaging MEMS-based probe of 2.8 mm diameter will be designed and manufactured. The plan is to apply MEMS design and wire bonding free packaging techniques for miniaturization of the probe. In this MEMS design the mirror will have high fill factor and bonding pads on the opposite chip side of the reflective mirror surface. The MEMS mirror and the other optical component will be packaged into the MEMS-based probe; the probe will be attached with the existing OCT system, and then will be tested for lung imaging. The proposed MEMS-based OCT system has the potential to be a low-cost tool for rapid diagnosis or screening of lung cancer at the point of care. It is also expected that the technology could be used for other OCT systems for internal organ imaging. If successful the proposed MEMS design and wire bonding-free (WBF) packaging technique can be applied virtually to all optical imaging systems including coherence, confocal, nonlinear and adaptive optical imaging. They can also be used in laser scanning displays and optical telecommunications. This effort may lead to the world's first MEMS-based OCT applicable to rapid diagnosis or screening of lung cancer at the point of care (e.g., bedside or office). Due to its low-cost and disposable nature, it is particularly suitable for field use without the need of sterilization equipments. Although the focus of this proposal is on a MEMS based endoscopic OCT system for bronchoscopy, the key technology developed can be adapted for other compact OCT systems for internal organ imaging. The MEMS-based endoscopic OCT probe is applicable to diagnosis and image-guided surgery of various internal cancers such as prostate, colon, rectal, and gastro-intestinal cancers. Wioptix is a company that received a SBIR Phase I grant for a project entitled: Development of Miniature Endoscopic Imaging Probes for In Vivo Noninvasive Optical Imaging for Early Diagnosis of Lung Cancer. Their Phase I project an Optical coherence tomography (OCT) imaging MEMS-based probe of 2.8 mm diameter will be designed and manufactured. The plan is to apply MEMS design and wire bonding free packaging techniques for miniaturization of the probe. In this MEMS design the mirror will have high fill factor and bonding pads on the opposite chip side of the reflective mirror surface. The MEMS mirror and the other optical component will be packaged into the MEMS-based probe; the probe will be attached with the existing OCT system, and then will be tested for lung imaging. The proposed MEMS-based OCT system has the potential to be a low-cost tool for rapid diagnosis or screening of lung cancer at the point of care. It is also expected that the technology could be used for other OCT systems for internal organ imaging. If successful the proposed MEMS design and wire bonding-free (WBF) packaging technique can be applied virtually to all optical imaging systems including coherence, confocal, nonlinear and adaptive optical imaging. They can also be used in laser scanning displays and optical telecommunications. This effort may lead to the world's first MEMS-based OCT applicable to rapid diagnosis or screening of lung cancer at the point of care (e.g., bedside or office). Due to its low-cost and disposable nature, it is particularly suitable for field use without the need of sterilization equipments. Although the focus of this proposal is on a MEMS based endoscopic OCT system for bronchoscopy, the key technology developed can be adapted for other compact OCT systems for internal organ imaging. The MEMS-based endoscopic OCT probe is applicable to diagnosis and image-guided surgery of various internal cancers such as prostate, colon, rectal, and gastro-intestinal cancers. "This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5)."

W
Wellan Medical

The Wellan ultraStand probe positioning system works as a third arm that aims to allow clinicians to perform image-guided procedures completely solo, resulting in major time savings and productivity improvements. The ultraStand frees assistants for more essential work, enabling ultrasound guidance that is truly hands-free. In clinical testing since 2005 at DHMC, the ultraStand is trusted b clinicians who use it by themselves regularly to perform ultrasound-guided nerve blocks, breast biopsies, and central lines. The ultraStand offers the confidence of a stable image along with the extra time and control afforded by the efficacy of having both hands available to perform interventional procedures. A product of collaboration between physicians of Dartmouth-Hitchcock Medical Center, engineers from Dartmouth's Thayer School of Engineering, and Wellan Medical's research and development team, the ultraStand aims to utilize multiple US and foreign patents-pending licensed from Dartmouth-Hitchcock Medical Center.

F
Formae

Formae, Inc. Formae is developing new approaches to cartilage replacement for osteoarthritis, using hydrogels that closely mimic the mechanical properties of hyaline cartilage. Formae's approach is in that it is minimally invasive and aims to provide for total rather than focal joint resurfacing. The company has a broad portfolio of issued and pending patents and a well-defined product and regulatory strategy. The technology can be applied to any joint, and has the potential to be implanted arthroscopically. Following the completion of ex-vivo mechanical testing that will meet a critical regulatory milestone, Formae will be seeking funds to conduct in-vivo implantation and biocompatibility testing. .

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.